Body Composition in Chronic Liver Disease

H Nishikawa, SK Kim, A Asai - International Journal of Molecular Sciences, 2024 - mdpi.com
Body composition has recently been attracting people's attention, not only from a cosmetic
standpoint but also from the perspective of health and longevity. The body is classified into …

[HTML][HTML] Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management

M Elsheikh, A El Sabagh, IB Mohamed… - World journal of …, 2023 - ncbi.nlm.nih.gov
Frailty and sarcopenia are frequently observed in patients with end-stage liver disease.
Frailty is a complex condition that arises from deteriorations across various physiological …

Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated …

I Efremova, R Maslennikov, M Zharkova… - Journal of Clinical …, 2024 - mdpi.com
(1) Background: The aim was to evaluate the effectiveness of the probiotic containing
Saccharomyces boulardii in the treatment of small intestinal bacterial overgrowth (SIBO) in …

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies

Y Zheng, J Feng, Y Yu, M Ling, X Wang - Archives of Pharmacal Research, 2024 - Springer
Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses
significant health risks in older adults worldwide. Both pharmacological and non …

Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis

MT Nie, PQ Wang, PM Shi, XL Hong… - Journal of …, 2024 - Wiley Online Library
Background Patients with decompensated cirrhosis face poor prognosis and increased
mortality risk. Rifaximin, a non‐absorbable antibiotic, has been shown to have beneficial …

Correlation between sarcopenia and cirrhosis: a meta-analysis

Y Cui, M Zhang, J Guo, J Jin, H Wang, X Wang - Frontiers in Nutrition, 2024 - frontiersin.org
Background The relationship between sarcopenia and cirrhosis is unclear. In this research,
our aim is to evaluate the prevalence of sarcopenia among individuals with liver cirrhosis …

[HTML][HTML] 利福昔明在终末期肝病患者中的应用

田皓月, 石小枫 - Advances in Clinical Medicine, 2024 - hanspub.org
终末期肝病唯一有效的治疗方式为肝移植, 但价格昂贵, 肝源短缺等原因限制了肝移植在临床上
的实际应用, 故改善生活质量及预后在终末期肝病患者的治疗中具有重要的意义 …